Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Survival and prognostic factors of patients with clinically localized prostate cancer.

Migowski A, Silva GA.

Rev Saude Publica. 2010 Apr;44(2):344-52. Erratum in: Rev Saude Publica. 2010 Jun;44(3):579.

2.
3.

A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.

Green GA, Hanlon AL, Al-Saleem T, Hanks GE.

Cancer. 1998 Sep 1;83(5):971-6.

PMID:
9731902
4.

[Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].

Akimoto S, Akakura K, Masai M, Isaka S, Shimazaki J.

Hinyokika Kiyo. 1990 Jul;36(7):783-91. Japanese.

5.

Prognostic markers in clinically localized prostate cancer.

Pettaway CA.

Tech Urol. 1998 Mar;4(1):35-42. Review.

PMID:
9568775
6.

[Effect of the natural history on management of adenocarcinoma of the prostate].

Schmid HP, Stamey TA, McNeal JE, Freiha FS, Redwine EA, Whittemore AS.

Urologe A. 1994 Mar;33(2):144-8. German.

PMID:
7513916
7.

The management of localized prostate cancer.

Clarke NW.

Br J Hosp Med. 1996 Mar 6-19;55(5):232-3. No abstract available.

PMID:
8777510
8.

Predictors of cancer progression in T1a prostate adenocarcinoma.

Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG.

Cancer. 1999 Mar 15;85(6):1300-4.

PMID:
10189135
9.

BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.

Schwartz AM, Man YG, Rezaei MK, Simmens SJ, Berg PE.

Mod Pathol. 2009 Jan;22(1):1-6. doi: 10.1038/modpathol.2008.168. Epub 2008 Oct 17.

10.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
11.
12.
13.

[Screening and prevention of prostate cancer].

Roosen A.

MMW Fortschr Med. 2010 May 13;152(19):37-9. German. No abstract available.

PMID:
20557000
14.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
15.

[Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].

Medvedev VL.

Voen Med Zh. 2004 Feb;325(2):50-4. Russian. No abstract available.

PMID:
15101295
16.

Prostate carcinoma with squamous differentiation: an analysis of 33 cases.

Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI.

Am J Surg Pathol. 2004 May;28(5):651-7.

PMID:
15105655
17.

[Prognostic significance of clinical stage including extent of disease (EOD) in prostate cancer].

Fujinami K, Kondo I, Miura T, Harada M, Uemura H, Hosaka M, Kawasaki C.

Hinyokika Kiyo. 1998 Apr;44(4):259-63. Japanese.

18.

Outcome based staging for clinically localized adenocarcinoma of the prostate.

D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A.

J Urol. 1997 Oct;158(4):1422-6.

PMID:
9302135
19.

[Clinical analysis of 169 patients with prostate cancer].

Okaneya T, Mizusawa H, Yoneyama T, Taguchi I, Komiyama I, Kawakami M, Hosaka K, Tsuruta T, Murata Y, Komatsu H, Misawa K, Kiyokawa H.

Hinyokika Kiyo. 1996 Aug;42(8):563-7. Japanese.

20.

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.

Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9.

PMID:
15145150

Supplemental Content

Support Center